Drug Profile


Alternative Names: Mountain cedar allergy immunotherapy - Immunomic; Mountain cedar allergy vaccine - Immunomic; Mountain cedar LAMP vaccine - Immunomic; Texas mountain cedar LAMP vaccine - Immunomic

Latest Information Update: 29 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunomic Therapeutics
  • Class Tree pollen allergy immunotherapies
  • Mechanism of Action Immunostimulants; Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Allergic rhinitis
  • No development reported Allergic rhinoconjunctivitis

Most Recent Events

  • 22 Nov 2016 Immunomic Therapeutics has patent protection for LAMP-Vax™ technology in USA
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Allergic rhinoconjunctivitis in USA (IM, Injection)
  • 01 Mar 2015 Immunomic Therapeutics completes a phase Ic trial in Allergic rhinitis in USA (Intradermal) (NCT02146781)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top